What is Zacks Research's Estimate for Novartis Q1 Earnings?

Novartis AG (NYSE:NVS - Free Report) - Analysts at Zacks Research reduced their Q1 2026 earnings estimates for shares of Novartis in a research report issued to clients and investors on Wednesday, January 15th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $2.07 per share for the quarter, down from their previous estimate of $2.09. The consensus estimate for Novartis' current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Novartis' Q2 2026 earnings at $2.25 EPS and FY2026 earnings at $8.96 EPS.

Several other equities research analysts also recently issued reports on the company. Erste Group Bank reiterated a "hold" rating on shares of Novartis in a report on Tuesday, November 19th. HSBC lowered shares of Novartis from a "hold" rating to a "reduce" rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets raised their price objective on shares of Novartis from $118.00 to $120.00 and gave the company a "market perform" rating in a research note on Wednesday, October 30th. Two research analysts have rated the stock with a sell rating and seven have given a hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $121.50.

Novartis Trading Down 0.4 %

NYSE:NVS traded down $0.35 during trading hours on Monday, reaching $97.51. 1,483,597 shares of the stock were exchanged, compared to its average volume of 958,711. Novartis has a twelve month low of $92.35 and a twelve month high of $120.92. The business has a 50-day moving average of $100.61 and a two-hundred day moving average of $109.01. The company has a market capitalization of $199.30 billion, a price-to-earnings ratio of 11.32, a PEG ratio of 1.36 and a beta of 0.57. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55.

Novartis (NYSE:NVS - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.94 by $0.12. The business had revenue of $12.82 billion for the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same period in the previous year, the firm earned $1.74 EPS.

Hedge Funds Weigh In On Novartis

Institutional investors and hedge funds have recently made changes to their positions in the stock. Integral Health Asset Management LLC grew its holdings in Novartis by 33.3% during the 2nd quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company's stock worth $31,938,000 after acquiring an additional 75,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Novartis by 115.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company's stock worth $26,797,000 after purchasing an additional 124,111 shares in the last quarter. Bank of Montreal Can increased its holdings in Novartis by 343.5% in the second quarter. Bank of Montreal Can now owns 657,903 shares of the company's stock valued at $70,652,000 after buying an additional 509,567 shares during the last quarter. CWA Asset Management Group LLC raised its stake in Novartis by 20.1% in the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company's stock valued at $3,001,000 after buying an additional 5,164 shares in the last quarter. Finally, Quantbot Technologies LP lifted its holdings in Novartis by 135.5% during the 3rd quarter. Quantbot Technologies LP now owns 39,976 shares of the company's stock worth $4,598,000 after buying an additional 22,998 shares during the last quarter. 13.12% of the stock is owned by institutional investors and hedge funds.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.